Trials / Conditions / Polycythemia Vera (PV)

Polycythemia Vera (PV)

18 registered clinical trials studyying Polycythemia Vera (PV) — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers NCT07529951	Eilean Therapeutics	Phase 1
Recruiting	A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms NCT07469891	Prelude Therapeutics	Phase 1
Not Yet Recruiting	A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV NCT07445893	Duan Minghui	N/A
Not Yet Recruiting	Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera NCT07341048	Hospices Civils de Lyon	N/A
Recruiting	MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225	MPN Research Foundation	—
Recruiting	Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera NCT07232290	Chengdu Zenitar Biomedical Technology Co., Ltd	Phase 2
Recruiting	A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) NCT06985147	Disc Medicine, Inc	Phase 2
Not Yet Recruiting	EVAluation of Erythrocytosis PRospEctive Cohort STudy NCT06785870	Cyrus Hsia	—
Recruiting	MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial NCT06541249	Icahn School of Medicine at Mount Sinai	Phase 2
Completed	A Study to Evaluate P1101 in Japanese PV Patients NCT06002490	PharmaEssentia Japan K.K.	Phase 3
Active Not Recruiting	Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms NCT06798805	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Completed	Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patient NCT04243122	Ottawa Hospital Research Institute	Phase 2
Recruiting	Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients NCT04655092	PharmaEssentia Japan K.K.	Phase 3
Completed	Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. NCT05421104	Novartis Pharmaceuticals	—
Completed	Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to NCT04182100	PharmaEssentia Japan K.K.	Phase 2
Active Not Recruiting	The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia NCT02577926	RWTH Aachen University	Phase 2
Completed	Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negati NCT01816256	University Health Network, Toronto	N/A
Available	Managed Access Programs for INC424, Ruxolitinib NCT04745637	Novartis Pharmaceuticals	—